Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Slagle Financial LLC

Slagle Financial LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 91.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,336 shares of the biopharmaceutical company's stock after selling 25,788 shares during the period. Slagle Financial LLC's holdings in Gilead Sciences were worth $262,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in GILD. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences in the first quarter valued at about $25,000. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences during the 1st quarter worth $29,000. Annis Gardner Whiting Capital Advisors LLC raised its stake in shares of Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 216 shares during the last quarter. Core Alternative Capital raised its stake in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares during the last quarter. Finally, Lee Danner & Bass Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter worth $41,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on GILD. Morgan Stanley lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Cantor Fitzgerald started coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Finally, Oppenheimer reduced their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $111.38.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider owned 121,152 shares of the company's stock, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the completion of the transaction, the chief financial officer directly owned 165,110 shares in the company, valued at approximately $18,190,168.70. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 58,500 shares of company stock valued at $6,340,745. Company insiders own 0.27% of the company's stock.

Gilead Sciences Trading Up 1.1%

Gilead Sciences stock traded up $1.30 during trading on Thursday, reaching $114.54. The company had a trading volume of 6,096,837 shares, compared to its average volume of 7,706,475. Gilead Sciences, Inc. has a 12-month low of $68.14 and a 12-month high of $119.96. The stock's 50 day moving average price is $107.62 and its two-hundred day moving average price is $104.50. The firm has a market capitalization of $142.48 billion, a price-to-earnings ratio of 24.11, a PEG ratio of 0.73 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm's revenue was down .3% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.32) earnings per share. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were paid a dividend of $0.79 per share. The ex-dividend date was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.76%. Gilead Sciences's dividend payout ratio is presently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.